1105662-95-0

Usage

Uses

Used in Pharmaceutical Industry:
2,5-Diazaspiro[3.5]nonane-2-carboxylic acid, 6,8-dioxo-, 1,1-diMethylethyl ester is used as a reactant for the preparation and structure-activity relationship (SAR) studies of tetracyclic MK2 (MAPKAP-K2) inhibitors. These inhibitors are of significant interest due to their potential role in the treatment of various diseases, including cancer and inflammatory disorders. The compound's unique structure allows for the development of highly specific and potent inhibitors that can modulate the activity of MK2, a key enzyme involved in cellular signaling pathways.
In the development of MK2 inhibitors, 2,5-Diazaspiro[3.5]nonane-2-carboxylic acid, 6,8-dioxo-, 1,1-diMethylethyl ester serves as a key building block, enabling the synthesis of a diverse range of tetracyclic structures with varying biological activities. By understanding the structure-activity relationship of these tetracyclic compounds, researchers can optimize their potency, selectivity, and pharmacokinetic properties, ultimately leading to the development of more effective therapeutic agents.

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 1002355-96-5 tert-butyl 3-(2-ethoxy-2-oxoethylidene)azetidine-1-carboxylate 
• 1111202-76-6 tert-butyl 3-amino-3-(2-ethoxy-2-oxoethyl)azetidine-1-carboxylate 
• 1265031-18-2 tert-butyl 3-(2-ethoxy-2-oxoethyl)-3-(3-ethoxy-3-oxopropanamido)azetidine-1-carboxylate 
• 1265051-29-3 C₁₅H₂₂N₂O₆ 
• 1105662-93-8 2-tert-butyl 7-methyl 6,8-dioxo-2,5-diazaspiro[3.5]nonane-2,7-dicarboxylate 

Downstream Products

• 1105662-97-2 2-(3-amino-1-tert-butoxycarbonyl-azetidin-3-ylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1H-1,7,9-triaza-cyclopenta[a]naphthalene-3-carboxylic acid lactame 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Furo-3-carboxamide derivatives and methods of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II

Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D-E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC50 50

HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS

The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and wa